Answers are grounded in this paper and cite their sources.
Pilot study compares HPV and PAX1 detection in urine and cervical swab samples for cervical intraepithelial neoplasia, indicating potential for less invasive screening.
Cervical cancer screening commonly requires clinician-collected cervical specimens, prompting interest in less invasive sampling approaches. This paired pilot study assessed agreement in high-risk human papillomavirus (hrHPV) detection and PAX1 methylation testing between cervical swab and urine specimens and evaluated their performance for cervical intraepithelial neoplasia grade 3 or worse (CIN3+). We enrolled 104 women with abnormal cervical cytology and histopathological confirmation. Among 94 pairs with valid hrHPV results, overall agreement was 94.7% (Cohen’s κ = 0.883; 95% CI, 0.783–0.983). Among 91 pairs with valid PAX1 results, agreement was 79.1% (κ = 0.446; 95% CI, 0.241–0.651). For CIN3 + detection, cervical swab and urine hrHPV testing showed sensitivities of 86.8% and 80.6% and specificities of 44.4% and 45.9%, respectively. Cervical swab and urine PAX1 methylation showed lower sensitivities of 52.6% and 41.2% but higher specificities of 85.7% and 90.0%, respectively. Rule-based combinations showed sensitivity–specificity trade-offs. In this referral-based cohort, urine hrHPV testing showed high agreement with cervical swab testing, whereas urine PAX1 methylation had lower agreement and sensitivity. Urine-based PAX1 testing remains exploratory and requires optimization and independent validation.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: